A new diabetes drug is revolutionizing treatment: one injection per week instead of seven.

The treatment of type 2 diabetes is witnessing a remarkable development with the emergence of a new drug called Awiqli, which is a long-acting insulin taken only once a week, instead of the traditional daily injections.

This innovation, which has received approval from the U.S. Food and Drug Administration (FDA), could change the way disease is managed for millions of patients around the world.

The drug is based on an active ingredient that releases insulin gradually into the body, ensuring that blood sugar levels remain stable throughout the week.

Its importance lies in simplifying the lives of patients, as it reduces the number of injections from 7 times a week to once, which may enhance adherence to treatment and alleviate the daily burden associated with diabetes.

Clinical studies

The drug was approved following a series of clinical studies that demonstrated its effectiveness in lowering glycated hemoglobin (A1C) levels, according to the U.S. Food and Drug Administration, which is the primary indicator for assessing diabetes control.

These studies included thousands of patients who used the drug in conjunction with other treatments, whether oral medications or additional meal-related insulin.

Despite these positive results, the drug is not without side effects. Low blood sugar is the most significant potential risk, along with injection site reactions, weight gain, and some skin changes. Doctors also warn of more serious complications such as severe allergic reactions or, in certain cases, heart problems.

Using Awiqli requires strict adherence to the doctor’s instructions, both in terms of dosage timing and injection method, along with regular monitoring of blood sugar levels. Patients should also be cautious when making changes to their lifestyle or medications, as these may affect the body’s response to insulin.

While this treatment represents a step forward in simplifying diabetes management, experts emphasize that its success depends on proper use and continuous medical follow-up, especially since its long-acting nature makes dose adjustments or dealing with emergencies more sensitive compared to traditional daily regimens.